<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957995</url>
  </required_header>
  <id_info>
    <org_study_id>0C-13-2</org_study_id>
    <secondary_id>NCI-2013-01731</secondary_id>
    <secondary_id>022-13</secondary_id>
    <secondary_id>0C-13-2</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT01957995</nct_id>
  </id_info>
  <brief_title>Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jina Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase I trial studies the side effects and best dose of nanosomal docetaxel&#xD;
      lipid suspension in treating patients with advanced solid tumors. Drugs used in chemotherapy,&#xD;
      such as nanosomal docetaxel lipid suspension, work in different ways to stop the growth of&#xD;
      tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the pharmacokinetics profile of nanosomal docetaxel lipid suspension (NDLS) in&#xD;
      patients with advanced solid tumors.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the safety and toxicity of NDLS in patients with advanced solid tumors.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 4 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive lowest dose nanosomal docetaxel lipid suspension intravenously (IV)&#xD;
      over 1 hour.&#xD;
&#xD;
      ARM II: Patients receive low dose nanosomal docetaxel lipid suspension IV over 1 hour.&#xD;
&#xD;
      ARM III: Patients receive high dose nanosomal docetaxel lipid suspension IV over 1 hour.&#xD;
&#xD;
      ARM IV: Patients receive highest dose nanosomal docetaxel lipid suspension IV over 1 hour. In&#xD;
      all arms, treatment may repeat every 21 days for up to 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 2013</start_date>
  <completion_date type="Actual">July 14, 2016</completion_date>
  <primary_completion_date type="Actual">May 29, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile of nanosomal docetaxel lipid suspension</measure>
    <time_frame>Pre-dose and post dose at 10, 20, 30, 40, 50, 60, 80, and 100 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours</time_frame>
    <description>Descriptive statistics of all pharmacokinetic parameters would be computed and reported for free and total docetaxel. Maximum blood concentration (Cmax), area under the curve (AUC)0-t, AUC0-infinity, time to Cmax (Tmax), terminal elimination rate constant (lambda z), half-life (t1/2), AUC percent extrapolated (%Extrap), clearance (CL), and volume of distribution (Vd) will be calculated.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I (lowest dose NDLS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive lowest dose nanosomal docetaxel lipid suspension IV over 1 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (low dose NDLS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive low dose nanosomal docetaxel lipid suspension IV over 1 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (high dose NDLS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive high dose nanosomal docetaxel lipid suspension IV over 1 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (highest dose NDLS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive highest dose nanosomal docetaxel lipid suspension IV over 1 hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nanosomal docetaxel lipid suspension</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (lowest dose NDLS)</arm_group_label>
    <arm_group_label>Arm II (low dose NDLS)</arm_group_label>
    <arm_group_label>Arm III (high dose NDLS)</arm_group_label>
    <arm_group_label>Arm IV (highest dose NDLS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (lowest dose NDLS)</arm_group_label>
    <arm_group_label>Arm II (low dose NDLS)</arm_group_label>
    <arm_group_label>Arm III (high dose NDLS)</arm_group_label>
    <arm_group_label>Arm IV (highest dose NDLS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have given written, personally signed and dated, informed consent to participate&#xD;
             in the study before initiating any study related procedures&#xD;
&#xD;
          -  Body mass index (BMI) at least 17 calculated as weight in kg/height in m^2&#xD;
&#xD;
          -  Must have histopathologically/cytologically confirmed primary tumors for which&#xD;
             docetaxel is an appropriate or reasonable treatment option&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Must have recovered from any toxic effects of previous chemotherapy or radiotherapy as&#xD;
             judged by the investigator to =&lt; grade 1&#xD;
&#xD;
          -  Previous chemotherapy/radiotherapy/targeted therapy should have been completed at&#xD;
             least 4 weeks prior to start of NDLS administration&#xD;
&#xD;
          -  Life expectancy of at least 6 months&#xD;
&#xD;
          -  Female patients of child bearing potential must have negative serum pregnancy test at&#xD;
             screening&#xD;
&#xD;
          -  Sexually active women, unless surgically sterile (at least 6 months prior to study&#xD;
             drug administration) or postmenopausal for at least 12 consecutive months, must use an&#xD;
             effective method of avoiding pregnancy (including oral, transdermal, or implanted&#xD;
             contraceptives [any hormonal method in conjunction with a secondary method],&#xD;
             intrauterine device, female condom with spermicide, diaphragm with spermicide,&#xD;
             absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile&#xD;
             [at least 6 months prior to study drug administration] sexual partner) for at least 4&#xD;
             weeks prior to study drug administration, during study and up to 30 days after the&#xD;
             last dose of study drug; cessation of birth control after this point should be&#xD;
             discussed with a responsible physician&#xD;
&#xD;
          -  In case of male patients: either patient partners or patients themselves must use an&#xD;
             effective method of avoiding pregnancy for at least 4 weeks prior to study drug&#xD;
             administration, during study and up to 30 days after the last dose of study drug or&#xD;
             till next chemotherapy cycle&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 gm/dl&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin =&lt; ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &lt; 2.5X ULN if alkaline&#xD;
             phosphatase &lt; 2.5 ULN&#xD;
&#xD;
          -  AST/ALT &lt; 1.5 X ULN if alkaline phosphatase &gt; 2.5 ULN&#xD;
&#xD;
          -  Alkaline phosphatase must be &lt; 5 x ULN on all cases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to docetaxel injection or any of its excipients&#xD;
&#xD;
          -  Intolerance to any antineoplastic agents belonging to the taxane family&#xD;
&#xD;
          -  Prior anticancer therapy within 28 days prior to the first day of study treatment&#xD;
&#xD;
          -  Participation in another experimental drug study within 30 days prior signing the&#xD;
             informed consent form (ICF)&#xD;
&#xD;
          -  Any of the following cardiac conditions:&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  New York State Heart Association (NYHA) class II-IV heart failure&#xD;
&#xD;
               -  Uncontrolled angina&#xD;
&#xD;
               -  Severe uncontrolled ventricular arrhythmias&#xD;
&#xD;
               -  Clinically significant pericardial disease&#xD;
&#xD;
               -  Electrocardiographic evidence of acute ischemic or active conduction system&#xD;
                  abnormalities&#xD;
&#xD;
               -  Evidence of abnormal cardiac conduction (e.g., bundle branch block or heart&#xD;
                  block) are eligible if their disease has been stable for the past six months *&#xD;
                  History of cardiac disease that met the NYHA classification class 2 or greater&#xD;
&#xD;
          -  Use of any recreational drugs or history of drug addiction&#xD;
&#xD;
          -  Known history of brain metastasis&#xD;
&#xD;
          -  Pre-existing motor or sensory neurotoxicity of a severity &gt;= grade 2 by National&#xD;
             Cancer Institute (NCI) criteria&#xD;
&#xD;
          -  Positive hepatitis screening (hepatitis screen includes hepatitis B surface antigen&#xD;
             [HBsAg], hepatitis C virus [HCV] and hepatitis A virus [HAV] [immunoglobulin M (IgM)]&#xD;
             antibody)&#xD;
&#xD;
          -  Known case of active infection including human immunodeficiency virus (HIV) infections&#xD;
&#xD;
          -  Any other condition that, in the investigator's judgment, might increase the risk to&#xD;
             the patient or decrease the chance of obtaining satisfactory data needed to achieve&#xD;
             the objectives of the study&#xD;
&#xD;
          -  Abnormal baseline findings considered by the investigator to indicate conditions that&#xD;
             might affect study endpoints&#xD;
&#xD;
          -  Donation of blood (1 unit or 350 mL) within 90 days prior to receiving the first dose&#xD;
             of study medicine&#xD;
&#xD;
          -  Known, existing uncontrolled coagulopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony El-Khoueiry</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>October 4, 2013</study_first_submitted>
  <study_first_submitted_qc>October 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>April 8, 2017</last_update_submitted>
  <last_update_submitted_qc>April 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

